Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Activated human platelets synthesize prostaglandin E(2) (PGE(2)), but its role in platelet function is less understood than thromboxane A(2).
• PGE(2) exerts its effects through multiple receptors: EP1, EP2, EP3, and EP4.
• The precise modulation of human platelet activity by PGE(2) via these receptors requires further investigation.

Purpose of the Study:

• To investigate the effects of PGE(2) and its analogs on in vitro human platelet function.
• To examine the expression of EP receptors on human platelets and megakaryocytes.
• To elucidate the mechanisms by which PGE(2) influences platelet activation and aggregation.

Main Methods:

• Human platelets were preincubated with PGE(2) or analogs, then stimulated with agonists.
• Platelet aggregation was measured using optical aggregometry.
• Intraplatelet calcium mobilization, VASP phosphorylation, P-selectin expression, and microaggregate formation were assessed by flow cytometry and stopped-flow methods.

Main Results:

• PGE(2) dose-dependently increased the velocity of the secondary phase of ADP-induced platelet aggregation and stabilized reversible aggregation.
• EP3 receptor agonists (11-deoxy-16,16-dimethyl PGE(2) and sulprostone) significantly enhanced ADP-induced aggregation and calcium mobilization.
• EP2 agonist butaprost inhibited ADP-induced secondary aggregation, while EP4 stimulation had minor inhibitory effects. All EP subtypes were expressed on platelets and megakaryocytes.

Conclusions:

• PGE(2) finely modulates human platelet responsiveness through distinct EP receptor pathways.
• EP3 receptor activation promotes platelet aggregation and calcium signaling.
• These findings provide a basis for developing novel antithrombotic therapies targeting EP receptor modulation.